Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

39.95
-0.1500-0.37%
Post-market: 39.950.00000.00%19:30 EDT
Volume:587.80K
Turnover:23.31M
Market Cap:3.85B
PE:-20.42
High:40.20
Open:39.85
Low:38.90
Close:40.10
52wk High:42.68
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.74
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.21
PE(LYR):-31.09

Loading ...

Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Loss $1.11 a Share, vs. FactSet Est of $1.05 Loss

MT Newswires Live
·
May 05

IDEAYA Q1 FY26 net loss widens to $98.5 million; revenue falls to $6.6 million

Reuters
·
May 05

IDEAYA Biosciences Inc - Reports ~$973 Mln Cash and Securities as of March 31, 2026; Cash Runway Into 2030 Unchanged

THOMSON REUTERS
·
May 05

IDEAYA Biosciences Inc - to Initiate Rtor Submission in May; Nda Filing Targeted for H2 2026

THOMSON REUTERS
·
May 05

IDEAYA Biosciences Q1 Collaboration Revenue USD 6.56 Million

THOMSON REUTERS
·
May 05

IDEAYA Biosciences Inc - Clinical Updates From Multiple Trials Planned for H2 2026

THOMSON REUTERS
·
May 05

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
May 05

IDEAYA Biosciences grants inducement stock options for 237,800 shares at $29.1 each

Reuters
·
May 01

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 01

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Butterfly Network (BFLY), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Apr 30

Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA

TIPRANKS
·
Apr 30

IDEAYA Biosciences: to Initiate Nda Submission From Darovasertib Optimum-02 Trial

THOMSON REUTERS
·
Apr 30

IDEAYA Biosciences Inc - to Initiate Rtor Submission in May, Nda Filing Completion Expected in H2 2026

THOMSON REUTERS
·
Apr 30

FDA agrees to review IDEAYA darovasertib-crizotinib NDA under RTOR program

Reuters
·
Apr 30

IDEAYA Biosciences announces annual shareholder meeting

Reuters
·
Apr 30

IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation

Simply Wall St.
·
Apr 22

IDEAYA to present complete OptimUM-02 darovasertib-crizotinib trial data at ASCO 2026

Reuters
·
Apr 21

IDEAYA Biosciences Inc : JP Morgan Raises Target Price to $81 From $78

THOMSON REUTERS
·
Apr 15

IDEAYA Biosciences Inc : Stephens Raises Target Price to $48 From $45

THOMSON REUTERS
·
Apr 15

Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says

MT Newswires Live
·
Apr 14